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ABSTRACT 
 
Bupropion is an atypical antidepressant with a unique aminoketone structure similar to 
amphetamines. A narrow therapeutic margin is evident from observational studies that show 
seizure activity with doses of 400-600 mg or higher.     
A 38-year old woman took an overdose of 6 grams of bupropion with 110 grams of alcohol. She 
presented to the Emergency Department with agitation, visual hallucinations and myoclonus of the 
upper limbs; eyes spontaneously open with isochoric and light reactive pupils with horizontal 
nystagmus; afebrile, normotensive (121/63 mm Hg) and tachycardic (120 beats/minute). The 
electrocardiogram revealed a sinus tachycardia with prolonged QT interval (QT/QTc: 0.46/ 0.537) 
and a QRS complex length in the upper limit of normal. Arterial blood gases revealed metabolic 
acidosis (pH = 7.16) with increased anion-gap (value=18). She developed mal epilepticus needing 
thiopental induced coma and Intensive Care Unit (ICU) admission.  She suffered prolonged 
symptoms including seizures before fully recovering.  
The narrow therapeutic range and the increasing use in the treatment of smoking cessation 
boosted the number of intentional and unintentional poisoning by this drug. Previous reports of 
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bupropion overdose almost all involve the immediate release formulation. There are some reports 
of overdose with sustained-release formulation, but there is limited information on its spectrum of 
toxicity.  
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1. INTRODUCTION 
 
Intentional drug overdose usually with multiple 
substances and alcohol is a reality in critically ill 
intoxicated patients, many of which needing 
admission to critical care environment. In recent 
years, scientific development promoted the 
emergence of many potential drugs with 
overlapping manifestations, requiring high 
demands on recognition, monitoring and 
treatment [1,2]. 
 
Bupropion is an atypical antidepressant with a 
unique aminoketone structure similar to 
amphetamines. It is thought that its mechanism 
of action comprises selective inhibitory effects on 
transporter and neuronal reuptake particularly on 
dopamine and serotonin but also norepinephrine 
and a moderated anticholinergic effect [3,4,5,6]. 
This agent was approved in 1986 as an 
antidepressant at a dose of 400 to 600 mg per 
day and promptly removed from the market for 
higher incidence of seizures, particularly in 
patients with bulimia, epilepsy or history of head 
trauma. It was reintroduced to the market in 1989 
in a lower dose range (maximum of 450 mg per 
day) and with contraindications in high risk 
populations [3,4,5,6,7]. Since 1997, bupropion 
was particularly important as adjunctive therapy 
in smoking cessation at a dose of 150 mg per 
day and in higher doses in cocaine addition, not 
as a substitute but by increasing the 
concentration of dopamine in the nucleus 
accumbens, traditionally linked to the sense of 
well-being and pleasure [5,6]. 
 
The narrow therapeutic range and the increasing 
use in the treatment of smoking cessation 
boosted the number of intentional and 
unintentional poisoning by this drug. Previous 
reports of bupropion overdose almost all involve 
the immediate release formulation, available in 
the United State but not everywhere else 
(including Western Europe). There are reports of 
the sustained-release formulation in overdose, 
but there is limited information on its spectrum of 
toxicity.  
 
The authors present a case of intentional 
overdose by sustained-release bupropion, with 
review of the literature regarding clinical effects 
and standards of therapeutic orientation. 
 
2. CASE REPORT 
 
A 38 year old woman with previous history of 
depression including two previous suicide 
attempts (at 21 and 28 years old) was admitted 
to the Emergency Department 2 hours after a 
voluntary intake of 6 grams of bupropion (20 pills 
of 300 milligrams of sustained release) and 110 
grams of alcohol. Medical and psychiatric history 
was notable only for depression. There was no 
history of epilepsy or eating disorders. She was 
taking no other medications and bupropion was 
prescribe by family doctor, two weeks ago, at 
300 mg day. On examination she presented with 
agitation, visual hallucinations and myoclonus of 
the upper limbs; the eyes were spontaneously 
open with isochoric and light reactive pupils and 
with spontaneous horizontal nystagmus; afebrile, 
normotensive (121/63 mm Hg) and tachycardia 
(120 beats/minute) with unremarkable 
cardiopulmonary auscultation. Arterial blood 
gases revealed metabolic acidosis (pH = 7.16) 
with increased anion-gap (value = 18). The 
electrocardiogram showed a sinus tachycardia 
with prolonged QT interval (QT/QTc: 0.46/ 0.537) 
and a QRS complex length in the upper limit of 
normal. She underwent medical treatment with 
gastric lavage without recovery of pills, followed 
by administration of activated charcoal. Four 
hours after presentation she suffered three 
generalized tonic-clonic seizures, resistant to the 
administration of diazepam and phenytoin 
evolving to mal epilepticus prompting ICU 
admission and thiopental induced coma. The 
blood alcohol level was 110 grams by enzymatic 
assay with alcohol dehydrogenase. Drug 
screening in urine (tricyclic antidepressants, 
benzodiazepines, opioids and amphetamines) 
was negative by fluorescence immunoassay.  
 
The patient had a benign course under anti-
comitial drugs, without paroxysmal activity on 
electroencephalogram and with 
electrocardiography normalization after 24h.   
 
She had aspiration pneumonia, treated with 
amoxicillin and clavulanic acid 2.2 g 8/8hours, as 
secondary complication.  
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Clinical stability allowed downstage to the high 
dependency unit three days after and further 
guidance to the Psychiatry ward. 
 
3. DISCUSSION 
 
Our article has focused on intentional bupropion 
ingestion with alcohol resulting in seizures. 
Fortunately, the majority of these patients had 
self-limited seizures and recovered without any 
permanent damage like how our patient. 
Seizures were more common when patients had 
co-ingested stimulants or alcohol, which may 
resulted in a further lower threshold. Although 
seizures often occur early, late presentation is 
also possible, particularly if other neurological 
symptoms are preceding, like tremors and 
hallucinations, as occurred in this case.  
 
Bupropion is an atypical antidepressant with a 
unique aminoketone structure similar to 
amphetamines, particularly important as 
adjunctive therapy in smoking cessation and 
cocaine addiction [3-7]. A narrow therapeutic 
margin is evident from observational studies that 
show seizure activity with doses of 400-600 mg 
or higher [6,8].     
 
Metabolized by multiple pathways without any 
preference it leads to the production of 3 active 
metabolites that prolonged the adverse effects - 
hydroxybupropion (~ 4 hours) 
treohydrobupropion (~ 6 hours), 
erythrohydrobupropion (~ 8 hours). The first one 
is to be considered the main determinant for the 
adverse effects of the drug [4,5,8,9]. 
 
The half-life is estimated to be 21 hours and may 
be extended by the simultaneous use of other 
substances, with particular emphasis on alcohol 
(as in the case here described) and monoamine 
oxidase inhibitors, or in the presence of a large 
amount of active metabolites, themselves with a 
longer half-life (8.9). The removal by 
hemofiltration or hemodialysis is ineffective and 
the lack of an antidote requires support of 
dysfunctions until the effective elimination of the 
drug [3] (Table 1). 
 
The toxicity of bupropion is expressed by a wide 
spectrum of clinical manifestations including 
gastrointestinal, neurological and cardiovascular 
symptoms [10-12] (Table 2). 
 
Adverse effects usually occur within 4 hours of 
taking the dose, but seizure activity may be 
delayed for several hours [13,14]. 
 
Gastrointestinal symptoms are present in about 
one third of patients namely nausea and 
vomiting, described as the earliest and usually 
self-limiting.  Neurological manifestations stand 
out by their frequency and exuberance. Tremors 
(24%), drowsiness (16%), agitation (32%), 
delirium and hallucinations (21%) are the first 
signs of intoxication, as in our patient. Seizures 
occur in 15-37% of patients, and generally are 
late manifestations and dose-dependent 
[6,10,11,13,14]. Delayed onset of seizure activity 
occurred up to 14 hours (mean, 4.3 hours) with 
overdoses on sustained-release bupropion [7]. 
Typically with multiple episodes of short duration 
and self-terminating and rarely generalized with 
toxic levels less than 3 grams of bupropion. 
However, nearly 5% of patients who had a 
seizure developed status epilepticus [15]. The 
sustained-release formulations and the 
association with alcohol (> 25grams) are 
enhancers and promote recurrence of seizures 
for up to 72 hours, although seizures occur with 
both therapeutic formulations of bupropion 
overdose [9,16]. Our patient took 6 grams of 
bupropion of sustained-release and 110 grams of 
alcohol and four hours after presentation, she 
suffered three generalized tonic-clonic seizures 
evolving to mal epilepticus. Likewise she 
experienced prolonged symptoms including 
evolution into mal epilepticus, needing ICU 
admission for three days before fully recovering. 
 
 
Table 1. Pharmacokinetics of the various pharmacological forms of bupropion [10,12] 
 
Bupropion formulation Immediate release 
100 mg tid 
Sustained-release 
150 mg bid 
Extended-release 
150 mg, 300 mg qd 
Absorption 1,5 hours 2,5 hours 5 hours 
Metabolites 3-4 hours 5-6 hours 7-8 hours 
Distribution Volume distribution: 19-21 L/Kg  
Protein binding: 77-88% 
Half-life of bupropion 21 ± 9 hours 
Half-life of active metabolites  20 – 37 ± 10 hours 
Elimination Renal, intestinal 
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Table 2. Clinical manifestations of bupropion toxicity [3-5,10-12,14] 
 
System Manifestations 
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain 
Neurological Tremors, agitation, visual hallucinations, seizures, insomnia, 
paresthesias, light headedness, headache, confusion, coma 
Cardiovascular Tachycardia, hypertension, QT and QRS prolongation, systolic 
dysfunction , electromechanical dissociation , cardiogenic shock 
Others Xerostomia , metabolic acidosis 
 
More recently, cases of cardiotoxicity have been 
reported with sinus tachycardia (83%), 
hypertension (56%), prolonged QT interval and 
abnormal interventricular conduction with high 
potential malignant arrhythmias [10,11]. These 
changes can cause systolic dysfunction and 
even cardiogenic shock with high risk of death. 
Despite tachycardia and prolonged QT interval, 
systolic dysfunction did not happen in this case. 
The pathophysiology of cardiac dysfunction 
remains unknown, although it is believed that the 
adjunctive therapy for the intoxication may have 
an influential role. With the exception of sinus 
tachycardia, other cardiac manifestations are 
uncommon with less than 1.5 g doses. Malignant 
arrhythmias and sudden death are only seen on 
massive poisoning. Death from cardiac causes 
rarely occurs with less than 10g poisoning [3,5]. 
The risk of toxicity and death may be increased 
with involvement of certain co-ingestants, 
especially alcohol [14,15]. The treatment of this 
poisoning is the support of dysfunctions until the 
effective elimination of the drug. Gastric lavage 
and oral administration of activated charcoal 
should be accomplished in the first hour after 
intake of the drug. Oral administration of 
additional doses of activated charcoal or 
intestinal irrigation is not recommended, except 
in cases of poisoning with sustained release 
formulations, with high potential delayed toxicity, 
which wasn’t performed in the case [3-5]. 
 
Seizures are often self-terminating but 
therapeutic intervention may be required, mainly 
in the case of sustained release bupropion 
intoxication or in association with alcohol. 
Anticomicial calcium channel blockers 
(carbamazepine, phenytoin) should not be used 
by favoring cardiotoxicity. In these situations 
benzodiazepines are the preferred approach, 
even in high dose and in refractory cases are 
recommended barbiturates drugs, as it was in 
the present case. The use of benzodiazepines is 
also effective in visual hallucinations, which 
should not be dealt with antipsychotic drugs that  
 
lower seizure threshold [3,4,5]. The 
electrocardiographic changes usually solve with 
supportive treatment, rarely requiring 
antiarrhythmic drugs. 
 
Dosage adjustment and restriction on 
prescription of bupropion improved the safety 
profile of this drug use. Nevertheless the 
increasing use of new formulations in the 
treatment of smoking cessation and the common 
association with other toxic agents, namely 
alcohol, enhanced dramatically the number of 
voluntary and involuntary intoxication. The most 
important adverse effects are reflected in the 
central nervous system with changes in the 
mental status and seizures and in the cardiac 
system with arrhythmias and QT prolongation. 
This entity usually has a benign course, except in 
cases of massive poisoning (> 10g) and in cases 
related to sustained-release formulations where 
adverse effects are delayed and may persist up 
to 72h, being the neurological system the most 
worrisome. In most series the risk of death is low 
but there is no data mortality rate. The lack of an 
antidote and the impossibility of effective 
elimination by hemofiltration or hemodialysis 
require an aggressive and prolonged monitoring 
of neurologic and cardiovascular systems up to 
at least 12 hours. The treatment is support of 
dysfunction, mainly neurological and 
cardiovascular which might require ICU 
admission as in the current case. 
 
4. CONCLUSION 
 
Bupropion, like other antidepressant agents, 
lowers seizure threshold. Further attention 
should be placed towards the lifetime presence 
of suicidal attempts or ideation, personal of 
familial history of medication abuse and 
substance use disorder, including alcohol.  This 
seems particularly true for drugs like bupropion 
SR, which albeit generally safe within standard 
ranges of doses, may pose serious and life-
threating conditions in case of intoxication. 
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Specifically, psych education and an accurate 
monitoring for bipolar hints even in course of 
DSM-IV defined “unipolar” major depressive 
episodes seems mandatory for this high-risk 
population, as already directed by the recent 
guidelines released by the FDA about the 
prescription of antidepressants in depressed 
patients.  
 
Our report is limited by lack of generalizability 
and high chance of confounding factors, namely 
the concomitant assumption of alcohol, but 
demonstrates the importance of recognizing the 
potential for deliberate self-poisoning and draws 
attention to physicians for carefully monitor 
patients taking any form of bupropion. 
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